JP2018537415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537415A5 JP2018537415A5 JP2018519031A JP2018519031A JP2018537415A5 JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5 JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018537415 A5 JP2018537415 A5 JP 2018537415A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- multivalent
- terminus
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15189665.1 | 2015-10-13 | ||
| EP15189665.1A EP3156417A1 (en) | 2015-10-13 | 2015-10-13 | Multivalent fv antibodies |
| PCT/EP2016/074642 WO2017064221A1 (en) | 2015-10-13 | 2016-10-13 | Multivalent fv antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537415A JP2018537415A (ja) | 2018-12-20 |
| JP2018537415A5 true JP2018537415A5 (enExample) | 2019-11-21 |
| JP6936497B2 JP6936497B2 (ja) | 2021-09-15 |
Family
ID=54325413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519031A Expired - Fee Related JP6936497B2 (ja) | 2015-10-13 | 2016-10-13 | 多価Ｆｖ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11572415B2 (enExample) |
| EP (2) | EP3156417A1 (enExample) |
| JP (1) | JP6936497B2 (enExample) |
| KR (1) | KR20180057720A (enExample) |
| CN (1) | CN108473577A (enExample) |
| AU (1) | AU2016336866B2 (enExample) |
| BR (1) | BR112018007445A2 (enExample) |
| CA (1) | CA3001765A1 (enExample) |
| IL (1) | IL258638B2 (enExample) |
| MX (1) | MX2018004547A (enExample) |
| SG (2) | SG11201803083XA (enExample) |
| WO (1) | WO2017064221A1 (enExample) |
| ZA (1) | ZA201802543B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250091329A (ko) | 2015-06-15 | 2025-06-20 | 누맙 세러퓨틱스 아게 | 이종 이량체 다중 특이적 항체 포맷 |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| WO2019175368A1 (en) | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| WO2019199916A1 (en) * | 2018-04-13 | 2019-10-17 | Eli Lilly And Company | Fab-based trispecific antibodies |
| EP3774914A2 (en) | 2018-04-13 | 2021-02-17 | Affimed GmbH | Nk cell engaging antibody fusion constructs |
| CN112384243A (zh) * | 2018-04-17 | 2021-02-19 | 英温拉公司 | 三价三特异性抗体构建体 |
| PL3843757T3 (pl) | 2018-08-27 | 2024-08-05 | Affimed Gmbh | Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała |
| US20220396635A1 (en) * | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| MX2023006573A (es) * | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
| US20230272069A1 (en) * | 2022-02-28 | 2023-08-31 | Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences | Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025235413A1 (en) * | 2024-05-05 | 2025-11-13 | Duke University | Compositions targeting cancer antigens and methods of use thereof |
| WO2026087751A1 (en) | 2024-10-24 | 2026-04-30 | Affimed Gmbh | Combination of immune cell engager and nk cell products |
| EP4751731A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane |
| EP4751777A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor |
| EP4751734A1 (en) | 2024-11-29 | 2026-06-03 | Affimed GmbH | Bispecific antibody construct dosage regimen for treating nsclc |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| ATE387458T1 (de) * | 1994-01-07 | 2008-03-15 | Mochida Pharm Co Ltd | Fas-antigenbindender ligand |
| US5989830A (en) * | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ATE346866T1 (de) * | 2001-09-14 | 2006-12-15 | Affimed Therapeutics Ag | Multimerische, einzelkettige, tandem-fv- antikörper |
| PL372144A1 (en) | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| WO2008007755A1 (en) * | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| RU2693078C2 (ru) * | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| EP2938637A2 (en) | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Multivalent binding protein compositions |
| WO2014201378A1 (en) * | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| KR20250091329A (ko) * | 2015-06-15 | 2025-06-20 | 누맙 세러퓨틱스 아게 | 이종 이량체 다중 특이적 항체 포맷 |
-
2015
- 2015-10-13 EP EP15189665.1A patent/EP3156417A1/en not_active Withdrawn
-
2016
- 2016-10-13 WO PCT/EP2016/074642 patent/WO2017064221A1/en not_active Ceased
- 2016-10-13 BR BR112018007445A patent/BR112018007445A2/pt not_active Application Discontinuation
- 2016-10-13 IL IL258638A patent/IL258638B2/en unknown
- 2016-10-13 SG SG11201803083XA patent/SG11201803083XA/en unknown
- 2016-10-13 EP EP16791328.4A patent/EP3362478A1/en not_active Withdrawn
- 2016-10-13 MX MX2018004547A patent/MX2018004547A/es unknown
- 2016-10-13 JP JP2018519031A patent/JP6936497B2/ja not_active Expired - Fee Related
- 2016-10-13 AU AU2016336866A patent/AU2016336866B2/en not_active Ceased
- 2016-10-13 SG SG10202004094VA patent/SG10202004094VA/en unknown
- 2016-10-13 CN CN201680073236.5A patent/CN108473577A/zh active Pending
- 2016-10-13 CA CA3001765A patent/CA3001765A1/en active Pending
- 2016-10-13 KR KR1020187013310A patent/KR20180057720A/ko not_active Ceased
-
2018
- 2018-04-11 US US15/950,733 patent/US11572415B2/en active Active
- 2018-04-17 ZA ZA2018/02543A patent/ZA201802543B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017176174A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| PE20231851A1 (es) | Proteinas que se unen a nkg2d, cd16 y clec12a | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| JP2017504578A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2014158485A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2014533239A5 (enExample) | ||
| JP2017513476A5 (enExample) | ||
| RU2015100656A (ru) | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения | |
| JP2020517287A5 (enExample) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| HRP20171608T1 (hr) | Protutijela koja vežu albumin i njihovi vezujući fragmenti | |
| JP2019502694A5 (enExample) | ||
| JP2016531924A5 (enExample) | ||
| AR076797A1 (es) | Anticuerpos triespecificos o tetraespecificos | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| JP2016538240A5 (enExample) | ||
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2018033454A5 (enExample) |